Case report of the successful use of semaglutide to achieve target BMI prior to renal transplant in two patients with end‐stage‐kidney‐disease

The following cases demonstrate a proof of concept for the safe and effective use of the glucagon‐like‐peptide‐1 receptor agonist (GLP‐1 RA) semaglutide for weight loss in obese, non‐diabetic, end stage kidney disease (ESKD) patients on haemodialysis (HD), who are unable to undergo renal transplanta...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology (Carlton, Vic.) Vic.), 2024-06, Vol.29 (6), p.371-374
Main Authors: Wallace, Rory, Hamblin, Peter Shane, Tully, Emma, Tran, Julina, Nelson, Craig, Levidiotis, Vicki
Format: Article
Language:English
Subjects:
Body Mass Index
Body weight loss
Clinical trials
Diabetes
Diabetes mellitus
dialysis
end‐stage‐kidney‐disease
Female
GLP‐1
Glucagon
Glucagon-Like Peptide-1 Receptor - agonists
Glucagon-Like Peptides - adverse effects
Glucagon-Like Peptides - therapeutic use
Hemodialysis
Humans
Kidney diseases
Kidney Failure, Chronic - complications
Kidney Failure, Chronic - surgery
Kidney Failure, Chronic - therapy
Kidney transplantation
Kidney Transplantation - adverse effects
Kidney transplants
Male
Middle Aged
Obesity
Obesity - complications
Renal Dialysis
Time Factors
transplantation
Treatment Outcome
Waiting Lists
Weight control
Weight Loss - drug effects
weight‐loss
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The following cases demonstrate a proof of concept for the safe and effective use of the glucagon‐like‐peptide‐1 receptor agonist (GLP‐1 RA) semaglutide for weight loss in obese, non‐diabetic, end stage kidney disease (ESKD) patients on haemodialysis (HD), who are unable to undergo renal transplantation due to obesity. Obesity is a common barrier to wait‐listing for renal transplantation with effective, broadly applicable weight loss strategies lacking. GLP‐1 RAs have been shown to be effective adjuncts to achieve weight loss in non‐diabetic obese people. However, the major clinical trials excluded patients with ESKD on dialysis. This paper outlines the successful use of semaglutide to achieve a target body mass index (BMI) prior to renal transplant wait‐listing in two obese, non‐diabetic, HD patients. These patients achieved a 16% and 12.6% weight loss in under 9 months with one now waitlisted and the other transplanted. This strategy has the potential for broader use in this patient cohort to improve wait‐list times by overcoming this common barrier to renal transplantation.
ISSN:1320-5358
1440-1797
DOI:10.1111/nep.14277